Active Clinical Trials

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate® System (LAANTERN) Prospective Multi‑Center Registry

Study Overview:

LAANTERN is a prospective, multi-center registry that will include data collection to evaluate procedural success, local control failure rate, and Quality of Life (QoL) in up to 1,000 patients and up to 50 sites.  The study is currently enrolling eligible patients who would like to participate.

Study Device and Procedure:

The LAANTERN Registry will use the NeuroBlate System, a minimally invasive robotic laser thermotherapy tool that uses MRI-guided laser energy to ablate brain lesions.

With NeuroBlate, the surgeon attempts to ablate (destroy) lesions, or abnormal tissue, in the brain.  Unlike traditional brain surgery, a procedure with the NeuroBlate System does not require a large opening in the skull.  Instead, doctors create a small hole in the skull, about the diameter of a pencil.  While the patient is in the MRI machine, the doctor guides a small laser device (probe) through the hole into the lesion.  The probe delivers laser light energy that heats and destroys the affected tissue.  Because the NeuroBlate System is MRI-guided, the neurosurgeon is able to visualize the specific area of the brain to be ablated.  The precise nature of the procedure helps to lessen the likelihood of harm to nearby healthy tissue.1,2,3,4

Study Eligibility:

You may qualify to participate in this study if you are planning to undergo the NeuroBlate procedure.

You may be a candidate if:

  • You are undergoing thermal therapy with the NeuroBlate System.
  • You provide written authorization and/or consent per requirements.
  • You are available for the required study follow-up.

To take the next step, please contact a study center for more information. Only a study doctor can decide if you are a candidate for the study.

Study Purpose and Follow-up:

This Registry is intended to further understand the performance and utilization of the NeuroBlate System in current standard of care and will collect baseline, procedural and follow-up data. If you qualify for the study and you decide to participate, you will be provided with questionnaires to complete after your procedure and you will have more contact with hospital staff regarding your well-being. Visits to the clinic will be done on an as-needed basis and as recommended by your doctor.

Find a Study Center:

Arizona

Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital & Medical Center
Phoenix, AZ
Site Principal Investigator: Kris Smith, MD
Contact: Odilette Trevizo, RN, CNRN
+1.602.406.1463
Odilette.Trevizo@DignityHealth.org

California

University of California, San Diego
La Jolla, CA
Site Principal Investigator: David Piccioni, MD
Contact: Lara Rose
+1.858.822.6575
ljrose@ucsd.edu

Connecticut

Yale University School of Medicine
New Haven, CT
Site Principal Investigator: Veronica Chiang, MD
Contact: Judith Hess
+1.203.737.6259
judith.hess@yale.edu

Florida

Advent Health Orlando
Orlando, FL
Site Principal Investigator: James Baumgartner, MD
Contact: Brooke Hartwell
+1.773.316.1514
brooke.hartwell@adventhealth.com

Kansas

University of Kansas Medical Center
Kansas City, KS
Site Principal Investigator: Patrick Landazuri, MD
Contact 1: Lindsay Richardson
+1.913.574.0412
lrichardson5@kumc.edu
Contact 2: Catherine Lauridsen
+1.913.588.4573
clauridsen2@kumc.edu

Kentucky

University of Louisville
Louisville, KY
Site Principal Investigator: Joseph Neimat, MD
Contact: Anna Williford
+1.502.852.7402
anna.williford@lousiville.edu

Norton Cancer Institute
Louisville, KY
Site Principal Investigator: David Sun, MD
Contact: Debbie Ritchey
+1.502.446.8544
debbie.ritchey@nortonhealthcare.org

Minnesota

University of Minnesota
Minneapolis, MN
Site Principal Investigator: Clark Chen, MD
Contact: Clark Chen, MD
+1.612.624.8117
ccchen@umn.edu

Children’s Hospital St. Paul
St. Paul, MN
Site Principal Investigator: Joseph Petronio, MD
Contact: Katherine Ingram
+1.612.813.6329
Katherine.Ingram@childrensmn.org

Missouri

Washington University
Saint Louis, MO
Site Principal Investigator: Albert Kim, MD
Contact: Jeanine Portell
+1.314.362.2940
jportell@wustl.edu

New York

New York University Langone Medical Center
New York, NY
Site Principal Investigator: Sylvia Kurz, MD
Contact 1: Malcolm Delara
+1.212.263.4414
malcolm.delara@nyulangone.org
Contact 2: Ankeeta Joshi
+1.212.263.4431
ankeeta.joshi@nyumc.org

Ichan School of Medicine at Mount Sinai
New York, NY
Site Principal Investigator: Constantino Hadjipanayis, MD
Contact: Ryan Adams
+1.212.241.8349
Ryan.Adams@mountsinai.org

SUNY Upstate Medical University
Syracuse, NY
Site Principal Investigator: Zulma Tovar-Spinoza, MD
Contact: Sean Huckins
+1.315.464.8477
huckinss@upstate.edu

North Carolina

Duke University Medical Center
Durham, NC
Site Principal Investigator: Peter Fecci, MD
Contact: Tammy O’Brien
+1.919.660.9329
tammy.obrien@duke.edu

Wake Forest
Winston-Salem, NC
Site Principal Investigator: Stephen Tatter, MD
Contact: Wendy Jenkins
+1.336.716.3842
wejenkin@wakehealth.edu

Ohio

University Hospitals Cleveland Medical Center
Cleveland, OH
Site Principal Investigator: Andrew Sloan, MD
Contact: Karen Devine
+1.213.368.0076
karen.devine@uhhospitals.org

Cleveland Clinic Foundation
Cleveland, OH
Site Principal Investigator: Alireza Mohammadi, MD
Contact: Teresa Allison
+1.216.444.6459
ALLISOT@ccf.org

Pennsylvania

Thomas Jefferson University
Philadelphia, PA
Site Principal Investigator: Kevin Judy, MD
Contact: Jaime Dougherty
+1.215.955.7962
Jaime.Dougherty@jefferson.edu

University of Pittsburgh Medical Center
Pittsburgh, PA
Site Principal Investigator: Taylor Abel, MD
Contact: Madison Remick
+1.216.407.1651
mar355@pitt.edu

Texas

MD Anderson
Houston, TX
Site Principal Investigator: Ganesh Rao, MD
Contact: Carmen Jacobs
+1.713.745.3246
cjacobs@mdanderson.org

Study Shows Seizure Freedom for Most Epilepsy Patients with Minimally Invasive Laser Ablation Procedure

Monteris Medical Announces the Publication of Positive Clinical Data for its NeuroBlate® Laser System for Patients with Brain Metastasis

Monteris Medical Reaches Milestone of 2,000 Patients with NeuroBlate® System

Disclosures

Monteris provides technology for neurosurgeons, which allows them to ablate (destroy with lethal heat) from the inside, brain lesions and brain tumors that may be difficult to approach via traditional methods. Technology includes the NeuroBlate System, AxiiiS, AtamA, and MiniBolt devices, which may be used together to apply the focused laser energy with little or no effect on surrounding healthy tissue. The NeuroBlate System provides clinicians a tool that offers near real-time control and MRI visualization of the therapy during laser ablation treatment.

All brain surgeries carry risk. Possible adverse events include, but are not limited to, hematoma, embolic events, edema, bleeding, cerebral spinal fluid (CSF) leakage, infection, unintended major tissue damage and permanent neurological deficits. Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions and potential adverse events.

Rx Only.

  1. Wilson TA, Karajannis MA, and Harter DH. Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int. 2014 May 8;5:64.
  2. Mohammadi AM and Schroeder JL. Laser interstitial thermal therapy in treatment of brain tumors – the NeuroBlate System. Expert Review of Medical Devices 2014 11:2, 109-119.
  3. Sloan AE, Ahluwalia MS, Valerio-Pascua J, et al. Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma: clinical article. J Neurosurg. 2013 Jun;118(6):1202-19.
  4. Carpentier A, McNichols RJ, Stafford RJ, et al. Laser thermal therapy: real-time MRI-guided and computer- controlled procedures for metastatic brain tumors. Lasers Surg Med. 2011 Dec;43(10):943-50.